Study #2024-1148
A phase 3, randomized, open-label study to compare the efficacy and safety of anitocabtagene autoleucel versus standard of care therapy in participants with relapsed/refractory multiple myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
Description
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM as measured by progression-free survival (PFS) per blinded independent review committee (IRC).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Phase III
Physician name:
Krina Patel
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-855-625-0962
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.